A r t i c l e s respectively (Supplementary
), whereas the lowcoverage whole-genome sequencing achieved an average of 10-fold physical coverage (Supplementary Table 4) .
Sequencing data were analyzed using stringent criteria to identify somatic single-base substitutions, indels and structural alterations (Online Methods). All single-base substitutions and indels were confirmed by an independent sequencing method (Online Methods), and only confirmed mutations were included in the described analyses. With the exception of one tumor, we found that neuroblastoma tumors had an average of 13 (range of 1-52) somatically acquired single-base substitution or indel mutations that would be predicted to result in non-silent changes in coding regions. The non-silent substitutions were predominantly C:G to A:T transversions ( Fig. 1 and Supplementary Table 5) , representing a mutation spectrum different from those of other pediatric and adult tumors [13] [14] [15] . Overall, we detected 368 mutations in 353 genes (Supplementary Table 5 ). The average number of somatic mutations in our study was similar to that previously reported for neuroblastoma 16 and slightly higher than the number in medulloblastomas, a pediatric tumor analyzed by exome sequencing 13 . The number of somatic mutations in most neuroblastomas were notably lower than the number of alterations observed in common adult solid tumors 14, 15 . One tumor-derived cell line, NB07C, had a substantially higher number of somatic mutations (169 non-silent changes) than the other neuroblastomas analyzed. This case was considered to be an outlier in this study but may represent a unique subset of cases if similar tumors are identified in future validation efforts.
Six samples were analyzed by both exome and high-coverage whole-genome sequencing, permitting independent validation of the somatic alterations as well as a comparison of these approaches for the detection of sequence alterations. Over 91% of the whole-genome and 94% of the whole-exome targeted bases were represented by at least ten reads (Supplementary Tables 2 and 3) . A total of 245 somatic alterations in coding regions were detected by either approach, with 219 mutations identified by whole-genome sequencing and 240 alterations identified by whole-exome sequencing. Exomic and genomic sequencing detected 98% and 89% of the mutations, respectively, consistent with similar comparisons made by others 17 .
In addition to single-base substitutions and indels, we analyzed copy-number changes corresponding to focal amplifications (≥5-fold copy-number gain) or homozygous deletions (<20 Mb in size), as these are likely to harbor potential oncogenes and tumor suppressor genes. There was an average of 2 such focal copy-number changes per tumor (range of 0-10 per tumor) whose boundaries encompassed at least 1 protein-coding gene (Supplementary Table 6 ); all were amplification events, and the majority included either MYCN or ALK as the putative target gene. One tumor amplicon (in NB1395T) encompassed LIN28B, which is downstream of MYCN and a putative neuroblastoma oncogenic driver 18, 19 . There were also 4 structural rearrangements per tumor that were within protein-coding genes (range of 0-18 per tumor; Supplementary Fig. 2 and Supplementary  Tables 4 and 7) . These included deletions, duplications and inversions within the same chromosome, as well as interchromosomal translocations. We did not find evidence of chromothripsis in these samples, although this has recently been reported in a subset of high-risk neuroblastoma tumors 16 .
Candidate driver genes and targeted analyses
The coding exons of all genes that were recurrently altered in the tumors analyzed by next-generation sequencing were examined by PCR and Sanger sequencing in 74 additional neuroblastoma cases ( Table 2 , Online Methods and Supplementary Table 1) . Integration of these data with next-generation sequencing data identified new alterations in a number of genes as well as in those previously known to be involved in neuroblastoma. The ALK receptor tyrosine For whole-exome, high-coverage whole-genome and targeted capture analyses, sequence coverage is indicated, whereas, for low-coverage whole-genome analyses, physical coverage is indicated. Figure 1 Number and type of somatic alterations detected in each neuroblastoma case. Data are included for nonsynonymous single-base substitutions, indels and splice-site changes (non-silent mutations), homozygous deletions and amplifications affecting protein-coding genes, and rearrangements with at least one breakpoint within the coding region of a gene. Asterisks indicate individuals for whom data on rearrangements and copy-number changes were not available. Inset, mutation spectra of somatic non-silent single-nucleotide mutations in 16 cases of neuroblastoma.
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A r t i c l e s kinase gene was found to be mutated in 8 of 90 cases (9%) in our discovery screen ( Table 2 and Supplementary Table 5 ). All eight sequence changes in ALK affected two amino-acid residues in the tyrosine kinase domain (p.Arg1275Gln, p.Arg1275Leu and p.Phe1174Leu); these alterations have been reported to lead to constitutive kinase activity 4, 8, 11 . A 15-fold amplification of the ALK gene was also identified in 1 of the 32 cases evaluated for structural changes and copy-number alterations (Supplementary Table 6 ). However, no ALK translocations were detected, suggesting that this mechanism of ALK activation, typical of large-cell lymphomas, nonsmall-cell lung cancers and inflammatory myofibroblastic tumors, is uncommon in neuroblastoma 20, 21 . Additionally, the MYCN oncogene was found to be focally amplified in 15 of the 32 neuroblastomas (47%), including 5 of the 6 neuroblastoma cell lines, consistent with the previously reported frequency of MYCN amplification in highrisk tumors and the cell lines derived from such tumors 7 ( Table 2 and Supplementary Table 6 ). Amplification of ODC1, a MYCN target gene important for oncogenicity in neuroblastoma 22 , was seen in 3 of 15 MYCN-amplified tumors (20%; none of which displayed copy-number changes of ALK). Other alterations in known cancerrelated genes included a change in the HRAS oncogene encoding a p.Glu61Lys alteration and single missense alterations in the PTCH1 tumor suppressor and in the EGF receptor family member ERBB4 (Supplementary Table 5 ).
In addition to these alterations, a number of mutations in genes not previously known to be involved in neuroblastoma were identified. The most prominent example involved intragenic hemizygous deletions targeting the ARID1B gene, encoding ATrich interactive domain 1B, which were detected in 3 of 32 tumors (9%) in the discovery screen (Fig. 2, Table 2 and Supplementary Table 7 ). The deletions in ARID1B were identified by virtue of their aberrantly spaced paired-end sequences and, owing to their small size and hemizygous nature, would have been difficult to detect using conventional copy-number analyses. These alterations included an 83-kb deletion encompassing exon 6 and a 147-kb deletion encompassing exons 6-9, both of which were predicted to result in frameshift and premature truncation of the gene products, and a 621-kb deletion that removed exons 1 and 2, including the translational start site ( Fig. 2 and Table 2 ). All these deletions, which were confirmed by PCR amplification and sequencing across the deletion junction, would be expected to abolish functional translation of the key downstream DNA-binding (ARID) and topoisomerase-II-associated (PAT1) protein domains of ARID1B. An additional tumor had an insertion mutation in the homologous ARID1A gene that would be predicted to lead to premature termination of the protein.
To investigate the prevalence of the specific alterations identified in the discovery screen, we designed a custom capture approach to selectively sequence and detect point mutations and structural alterations in the genomic regions of ARID1A, ARID1B, ALK and MYCN in 40 additional neuroblastoma cases ( Supplementary Fig. 1 , prevalence screen). These analyses yielded an average sequence coverage of 723-fold per targeted base ( Supplementary Tables 1 and 8 ). Through these analyses, we were able to identify an intragenic hemizygous deletion and a splice-site mutation and a missense mutation in ARID1B in two additional tumors, as well as an additional intragenic deletion in a previously analyzed sample (NB05) (Fig. 2 , Table 2 and Supplementary  Tables 5 and 7) . Collectively, ARID1B point mutations or intragenic deletions were identified in 5 of 71 neuroblastoma cases (7%) ( Fig. 2 and Table 2 ). We further identified hemizygous deletions encompassing the entire coding region of ARID1B in the distal region of 6q in 5 additional cases (Supplementary Table 6 ). Furthermore, point mutations of ARID1A were identified in three additional cases, two of which led to biallelic inactivation through mutation predicted to result in premature termination of the protein and deletion of the alternative allele at 1p36 (Fig. 2, Table 2 and Supplementary Table 5 ). All of these alterations Table 2 and Supplementary Tables 5 and 6 ). ARID1B is a member of the SWI/SNF transcriptional complex that is thought to regulate chromatin structure 23 . Mutations recently identified in ARID1B suggest that it may serve as a driver of tumorigenesis in a small fraction of hepatocellular 24 , breast 25 , ovarian 26 and medulloblastoma 27, 28 tumors. Our findings in our integrated genomic analyses of five independent structural alterations and two sequence changes, the majority of which would result in a truncated protein, strongly support this gene as a contributor to neuroblastoma oncogenesis (passenger probability P < 0.001). Notably, we found sequence alterations in other genes involved in chromatin regulation in neuroblastoma. These included two frameshift, one nonsense and one missense mutation in ARID1A, another SWI/SNF complex member, nonsense mutations in the histone acetyltransferase (HAT) genes EP300 and CREBBP and missense mutations in the SWI2/SNF2 family member TTF2 gene, the histone demethylase gene KDM5A and the chromatin-remodeling zinc finger gene IKZF1. Genes involved in chromatin structure or remodeling have been implicated in human cancers through the identification of a high frequency of alterations of ARID1A in ovarian clear-cell carcinomas 26 and SMARCB1 in malignant rhabdoid tumors 29 , alterations of PBRM1 in renal cell carcinomas 30 , alterations of EP300 and CREBBP in transitional cell carcinomas of the bladder 31 and B-cell lymphomas 32 , alterations of DAXX and ATRX in pancreatic endocrine tumors 33 and inactivation of the histone methyltransferases MLL2 and MLL3 in medulloblastomas 13 , among other findings [34] [35] [36] . Of note, ATRX has recently been shown to be mutated in neuroblastoma tumors from adolescents and young adults (≥12 years old) 12 but would not have been expected to be altered in a substantial fraction of the affected individuals evaluated in our study (median age of diagnosis of <2 years old, range from <1-6 years old).
Personalized genomic biomarkers for neuroblastoma patients
Although the number of sequence alterations in neuroblastomas was low compared to in adult tumors, the frequency of recurrent structural rearrangements in neuroblastomas was relatively high. Every tumor had at least 1 rearrangement (range of 1-66), and all cases that had recurrent copy-number changes of MYCN, ARID1B or ALK also had rearrangements at these loci. Such rearrangements are not present in normal cells and could therefore be useful as biomarkers of neuroblastoma. Given the poor treatment outcomes for many patients with neuroblastoma, the availability of noninvasive testing for biomarkers to detect minimal residual disease after surgery and to measure molecular response to chemotherapy would be useful for clinical management of patients with neuroblastoma.
To demonstrate the feasibility of this approach, we selected personalized biomarkers on the basis of the rearrangements present in the cancers analyzed 37 . This was performed through analysis of either whole-genome sequencing or capture and sequencing of the MYCN locus to identify structural alterations associated with new rearrangement junctions not present in the germline (Online Methods). We have previously shown that tumor-specific rearrangements have 
npg
A r t i c l e s the potential to serve as highly sensitive biomarkers for tumor detection and monitoring 37 , and measurements of these would therefore be expected to have fundamental advantages over the measurement of wild-type sequences, including wild-type MYCN DNA 38 , in patients with neuroblastoma. Notably, tumors with and without MYCN amplification both had identifiable somatic rearrangement biomarkers, and, in three cases in which serum was available at the time of diagnosis, we were able to detect and quantify such specific tumor rearrangements in the subjects' sera ( Table 3 and  Supplementary Table 9 ). Quantitative analyses showed that there was much more tumor DNA freely floating in the serum than in circulating cells, suggesting that the cell-free compartment of blood may represent a more sensitive source for the detection of tumor burden ( Table 3) . We developed personalized rearrangement biomarkers to monitor circulating tumor DNA (ctDNA) in serial plasma samples from four additional cases of neuroblastoma obtained during a postconsolidation minimal residual disease (MRD) immunotherapy trial 39 ( Supplementary Fig. 3) . In two cases, NB2885T and NB2870T, the ctDNA was detected at the end of standard high-risk neuroblastoma therapy, and, despite MRD immunotherapy, these individuals relapsed and eventually died from disease. The prolonged reduction in ctDNA levels in NB2885T during immunotherapy may be an indication of therapeutic response, whereas the marked increase in ctDNA in NB2870T correlated with clinical relapse during the trial period. In cases NB6321T and NB2464T, no ctDNA was detectable, and these individuals were alive at the last follow-up over 1 and 4 years later, respectively. These data demonstrate that ctDNA levels may be a useful surrogate for the level of clinical disease and that the presence of ctDNA may be a highly sensitive and specific predictor of minimal residual disease and subsequent relapse 40 .
ARID1 alterations and clinical correlates
These genome-wide sequence analyses suggest that neuroblastoma tumors are driven by a relatively small number of somatically acquired alterations, and genes involved in chromatin remodeling, including ARID1B and ARID1A, were enriched for alterations. ARID1 family genes are integral components of the SWI/SNF neural progenitorspecific chromatin-remodeling BAF complex that is essential for the self-renewal of multipotent neural stem cells 41 . Tumor-specific deletions encompassing ARID1B have been reported in central nervous system (CNS) tumors 42 , and multiple members of this complex have been identified as tumor suppressor genes 26, 41 . We found that high expression of members unique to the neural progenitor BAF complex correlated with a high-risk neuroblastoma phenotype, whereas high expression of components of the neuron-specific BAF complex or downstream neuritogenesis target genes correlated with lower risk neuroblastoma (Supplementary Fig. 4) . These data support a model in which disrupted BAF complex signaling may preserve an undifferentiated progenitor state.
This model suggests that alterations in ARID1 genes correlate with a more aggressive neuroblastoma phenotype. All but one of the individuals with alterations in ARID1A or ARID1B died of progressive disease, including a child with low-risk neuroblastoma (a group with a survival probability of >98%). ARID1 gene alterations were associated with inferior overall survival of 386 d compared to 1,689 d for individuals without such alterations (hazard ratio = 4.49, 95% confidence interval (CI) = 1.24-16.33; P = 0.0226, log-rank test; Fig. 3 and Supplementary Table 10 ). An analysis that also included hemizygous deletions of the entire coding region of ARIDB further increased the significance of the survival difference between individuals with mutant ARID1B or ARID1A and those with wild-type genes (hazard ratio = 6.41, 95% CI = 1.93-21.25; P = 0.0024, log-rank test). The median survival of individuals with ARID1 gene alterations was lower than that observed for any other genetic alteration assessed, including MYCN amplification (median survival of 726 d), providing a potential marker for early therapy failure and disease progression.
DISCUSSION
This study highlights the importance of integrated genomic analyses, including detection of sequence alterations, copy-number changes and rearrangements, which can now be performed using massively parallel sequencing approaches to identify subtle genomic changes. Despite the comprehensive efforts of this study, some alterations may not have been detected. First, a small fraction of the exome was not analyzed, either because of low sequence coverage in the whole-genome analyses or inadequate capture in the exome analyses. Second, it is possible that point mutations in non-coding regions of the genome may be involved in neuroblastoma. Data for such mutations were obtained for six neuroblastoma cases and did not identify any clear clustering of alterations; analysis of additional neuroblastoma cases could be useful to further interpret the potential consequences of these non-coding changes. Third, germline neuroblastoma susceptibility variants have been identified 43, 44 , and additional variants like these remain to be discovered that may be present in our neuroblastoma cases. Fourth, it is possible that epigenetic alterations contribute to the initiation or progression of neuroblastomas. This possibility is intriguing, given the new data on ARID1B and ARID1A in this tumor type. Finally, although rearrangements and copy-number changes were detected in a genome-wide fashion, many of these occurred in non-coding regions, and their functional roles remain to be elucidated.
Our data add to the growing knowledge of the genomic landscapes of human cancers. They are consistent with the idea that pediatric tumors do not require as many genetic alterations as typical adult cancers 13, 45 . Although few alterations were identified in known therapeutically targetable oncogenes such as ALK, there are many other alterations, both subtle and large, that are found in these cancers, and many of these affect chromatin modifiers. These data highlight the important connection between genetic alterations in the cancer genome and epigenetic pathways and provide new avenues for research and disease management in patients with neuroblastoma. 
npg

ONLINE METhODS
Samples obtained for sequencing analyses. Neuroblastoma tumor DNA (from cell lines and primary tumors), matched germline DNA (from peripheral blood or lymphoblastoid cell line) and serum or plasma from affected individuals were obtained from the Children's Oncology Group (COG) cell line repository and the COG Neuroblastoma biobank following committee approval (study COG NB 2008-02). Informed consent for research use was obtained from all subjects and/or parents at the enrolling COG member institution before tissue banking or cell line generation, and study approval was obtained from The Children's Hospital of Philadelphia Institutional Review Board. All samples were short tandem repeat (STR) genotyped to confirm identity. Primary tumor samples were selected from individuals with COG high-risk disease, and specimens were verified to have >75% viable tumor cell content by histopathology assessment. Serial plasma samples for MRD assays were obtained from individuals enrolled in the COG ANBL0032 immunotherapy study.
Massively parallel paired-end sequencing and somatic mutation identification. Genomic DNA libraries were prepared and captured following Illumina's suggested protocol with the modifications described in the Supplementary Note or by Personal Genome Diagnostics. DNA libraries were sequenced with the Illumina Genome Analyzer IIx and/or HiSeq instruments, yielding 100 or 200 base pairs of sequence from the final library fragments for highcoverage exome and/or low-coverage genome and high-coverage genome analyses, respectively. Sequencing reads were analyzed and aligned to human genome hg18 with the Eland algorithm in CASAVA 1.7 software (Illumina). Reads were mapped using the default seed-and-extend algorithm, which allowed a maximum of two mismatched bases in the first 32 bp of sequence. Identification of somatic alterations was performed as previously described [46] [47] [48] [49] using a next-generation sequencing analysis pipeline that enriched for tumorspecific single-nucleotide alterations and small indels. Briefly, for each position with a mismatch (compared to the hg18 reference sequence using the Eland algorithm), the read coverage of the mismatched and wild-type sequence at that base was calculated. A candidate mismatched base was identified as a mutation only when (i) two or more distinct paired tags contained the mismatched base; (ii) the number of distinct paired tags containing a particular mismatched base was at least 7.5% of the total distinct tags and (iii) the mismatched base was not present in >0.5% of the tags in the matched normal sample. Candidate somatic point mutations identified by next-generation sequencing approaches were confirmed by an independent sequencing method (either a different next-generation sequencing approach or PCR followed by Sanger sequencing; Supplementary Table 5) .
Evaluation of genes in additional tumors and matched normal controls.
For 12 selected genes that were somatically altered, the coding region was sequenced in a validation set composed of an independent series of 74 additional neuroblastomas and matched controls. These genes included ALK, ANKRD34B, ARID1B, ARID1A, FAR1, PRSS16, PRSS23, RASGRP3, TTLL6, VANGL1, VCAN and ZHX2. PCR amplification and Sanger sequencing analyses were performed following protocols described previously 15 .
Identification of somatic copy-number alterations. Single tags passing filter were grouped by genomic position in non-overlapping 3-kb bins. A tag density ratio was calculated for each bin by dividing the number of tags observed in the bin by the average number of tags expected to be in each bin (on the basis of the total number of tags obtained for chromosomes 1 to 22 for each library divided by 849,434 total bins). The tag density ratio thereby allowed a normalized comparison between libraries containing different total numbers of tags. A control group of libraries made from the six matched normal highcoverage whole-genome samples from Supplementary Table 1 and six additional normal samples (Co84N, Co108N, B5N , B7N 37 and CEPH (Centre d'Etude du Polymorphisme Humain) samples NA07357 and NA18507) was used to define areas of germline copy-number variation or that contained a large fraction of repeated or low-complexity sequences. Any bin where at least two of the normal libraries had a tag density ratio of <0.25 or >1.75 was removed from further analysis. For all samples analyzed with low-coverage whole-genome sequencing (Supplementary Table 4) , amplifications were identified as three or more bins with tag ratios of >2, separated by no more than ten intervening bins with a tag ratio of <2. For all amplifications, at least one bin had a tag ratio of ≥5. For samples with high-coverage whole-genome sequencing (Supplementary  Table 3 ), homozygous deletions were identified as three or more bins with tag ratios of <0.25, separated by no more than ten intervening bins with a tag ratio of >0.25. Single-copy gains and losses were identified through visual inspection of tag density data for each sample.
For all samples analyzed with targeted capture sequencing, the tag ratio for each gene was calculated as the average read coverage for the gene divided by the average read coverage of the ALK, ARID1A and ARID1B genes (MYCN was not used, as it is frequently amplified). These values were normalized to the average coverage for each gene in a normal sample. Amplifications and hemizygous deletions were identified if the tag ratio for a gene was ≥5.0 or <0.65, respectively. Hemizygous deletions were confirmed through LOH analyses of SNPs in the genomic region of each gene.
Six samples with high-coverage whole-genome sequencing were analyzed for amplifications at the MYCN locus. The boundary coordinates for these amplifications were compared, and a 1-Mb region (hg18 chr. 2: 15.5 Mb-16.5 Mb) was identified that contained at least one amplification boundary region from each sample.
Identification of somatic rearrangements. Somatic rearrangements were identified by querying aberrantly mapping reads from one flow cell of an Illumina Genome Analyzer IIx run (100-bp paired-end reads) or up to two lanes of an Illumina HiSeq Genome Analyzer run (50-bp paired-end reads) to achieve a physical coverage of >8×. The discordantly mapping pairs were grouped into 1-kb bins when at least two distinct tag pairs (with distinct start sites) spanned the same two 1-kb bins (known bins that contained aberrantly mapping tags were removed 37 , as were 1-kb bins involved in known germline structural alterations 50 ).
To identify all high-confidence genomic rearrangements, candidate rearrangements were filtered using the described criteria and were required to have at least one tag sequenced across the rearrangement breakpoint. Breakpoints were determined using BLAT alignment to the human genome sequence (hg18) 51 . To ensure that no recurrent rearrangements in coding genes were missed, genes that harbored rearrangements were evaluated for all candidate rearrangements without the requirement that the breakpoint be present in a sequenced tag, and any recurrent gene rearrangement was further analyzed. Candidate rearrangements were confirmed as somatic when a 10-µl PCRbased reaction (containing 5.9 µl of H 2 O, 1 µl of 10× PCR buffer, 1 µl of 10 mM dNTPs, 0.6 µl of DMSO, 0.4 µl of 25 µM primers, 0.1 µl of Platinum Taq and 1 µl of DNA, 3 ng/µl) resulted in the amplification of a product of the expected size in the tumor but not in the matched normal sample on a 1% ethidium bromide-stained agarose gel. Using this stringent pipeline, of the 26 candidate genomic rearrangements tested, 25 were confirmed as somatic (96%) as well as 15 of the 16 candidate rearrangements tested that were identified by the MYCN capture sequencing method (94%). In all five cases of ARID1B somatic rearrangement, Sanger sequencing was performed on the PCR products to identify the breakpoints at base-pair resolution. For biomarker analyses, rearrangements were identified with the described method, with a subsequent PCR product sequenced and aligned using BLAT to hg18 (ref. 51) to design primers to amplify a PCR product in the serum, plasma or peripheral blood of 70-120 bp in size.
Quantification of tumor burden in serum and peripheral blood. ctDNA was amplified using 2× Phusion Flash PCR Master Mix and patient-specific primers (at a final concentration of 0.5 µM each) in DNA isolated from serum or plasma and DNA isolated from peripheral blood cells. Subsequently, the level of tumor DNA was quantified after amplification by digital PCR on SYBR Green I-stained 10% TBE gels 37 .
Gene expression analyses. For gene expression profiling by Affymetrix U95Av2 microarrays, the expression measures for each probe set were extracted and normalized using robust multiarray average protocols from raw CEL files as described previously 52 . Basic linear correlation and regression was used to define r, r 2 and two-tailed P values to assess correlation among gene expression values. 
